MBOT Microbot Medical

Microbot Medical Receives Notice of Allowance for U.S. Patent Covering a System for Reducing Dialysis Shunt Stenosis

Microbot Medical Receives Notice of Allowance for U.S. Patent Covering a System for Reducing Dialysis Shunt Stenosis
EN
07/10/2020

Underlying

MBOTMicrobot Medical

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Microbot Medical

 PRESS RELEASE
Free
MBOT Microbot Medica...

Microbot Medical Announces Strategic Collaboration with Stryker Corpor...

Microbot Medical Announces Strategic Collaboration with Stryker Corporation to Develop the LIBERTY® Robotic System for Neurovascular Applications HINGHAM, Mass., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company. The company will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System to develop the world’s first dedicated robotic procedural kits for use in certain n...

December 27, 2021 1 EN
 PRESS RELEASE
Free
MBOT Microbot Medica...

Microbot Medical Secures Third Patent for the LIBERTY® Robotic System ...

Microbot Medical Secures Third Patent for the LIBERTY® Robotic System in the United States; Success of Protecting Novel Intellectual Property Complements Recent Design Freeze Achievement HINGHAM, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a third patent application covering the Company’s LIBERTY® Robotic System. The Company has secured all three U.S. patents during 2021. Globally, the Company now has 47 patents issued/allowed and 26 pending patent a...

December 23, 2021 1 EN
 PRESS RELEASE
Free
MBOT Microbot Medica...

Microbot Medical Initiates Search for U.S. Clinical Sites for the LIBE...

Microbot Medical Initiates Search for U.S. Clinical Sites for the LIBERTY® Robotic System HINGHAM, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has and will continue to implement key initiatives that will prepare the LIBERTY® Robotic System for commercialization. In conjunction with recently announced design freeze, Dr. Eyal Morag, Microbot’s Chief Medical Officer, traveled to the United States to establish a clinical infrastructure with multiple sites and leading physicians for the commencement of a human clinical trial, which is expecte...

December 22, 2021 1 EN
 PRESS RELEASE
Free
MBOT Microbot Medica...

Microbot Medical Achieves Design Freeze of the LIBERTY® Robotic System...

Microbot Medical Achieves Design Freeze of the LIBERTY® Robotic System; Meets Previously Stated Milestone Timeline Live Demonstration of the LIBERTY Robotic System is Planned for January 10th in San Francisco, CA HINGHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) achieved the design freeze objective for the LIBERTY® Robotic System. This milestone demonstrates the continued progress towards the commercialization of the world’s first fully disposable robotic system. The Company’s ability to reach this milestone within the previously stated timeframe ref...

December 15, 2021 1 EN
 PRESS RELEASE
Free
MBOT Microbot Medica...

Microbot Medical Secures Additional Patent for the LIBERTY® Robotic Sy...

Microbot Medical Secures Additional Patent for the LIBERTY® Robotic System in the United States HINGHAM, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance for a second patent application covering the Company’s LIBERTY® Robotic System. Globally, the Company now has 46 patents issued/allowed and 24 pending patent applications and is continuously submitting applications to protect its Intellectual Property. “We believe that the U.S. is the largest and most significa...

November 19, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch